Eli Lilly And Co (NYSE:LLY) recently posted strong quarterly results amid robust growth from its diabetes and weight-loss ...

Novo Nordisk A/S remains a Strong Buy despite semaglutide's Alzheimer's trial miss. Click for NVO growth drivers, solid ...

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

Despite recent setbacks, Novo Nordisk offers strong long-term investment potential in diabetes and obesity. Click here to ...

This application is based on the encouraging results from the Phase 3 registration clinical study GLORY-2 (NCT06164873) of mazdutide 9 mg in Chinese adults with moderate to severe obesity. The study ...

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without ...

Labour Codes do not create flexible work environment legal, rate cuts may revive market sentiments, nominal GDP of over $11 ...

Novo Nordisk stock price has suffered a harsh reversal this year as the company’s woes have escalated. What next for the stock?

A pill version of Novo Nordisk A/S’s Ozempic failed to slow the progression of Alzheimer’s disease in a pair of high-risk ...

Vascular dementia is the second-most common form of dementia after Alzheimer's. About 2.7 million people in the U.S. are thought to have mixed dementia or vascular dementia, which is caused by strokes ...

Eli Lilly and Company (NYSE: LLY) today announced that new data from across its breast oncology portfolio and pipeline will ...

In exchange for at least 25% representation in Players Era, the Big 12 hopes to earn back big money on its commitment. "Over ...